Preparation process and application of uric acid reducing composition based on medicinal and edible medicinal materials

Abstract

The invention provides uric acid reducing granules of a medicinal and edible plant composition as well as a preparation process and application of the uric acid reducing granules. The uric acid reducing granules are prepared from the following raw materials in parts by weight: a honeysuckle flower extract, a chicory extract, a rhizoma polygonati extract, a poria cocos extract, a mulberry leaf extract, fructus gardeniae, herba taraxaci, rhizoma galangae, radix ginseng, herba cistanche and maltitol stevioside. According to the present invention, by compounding the various medicinal and edible plant extracts and the sweetening agent, the activity of xanthine oxidase in the body of the patient can be inhibited so as to inhibit the generation of uric acid in the body, the excretion of uric acid in the body of the patient can be promoted so as to effectively reduce the blood uric acid level in the body of the patient, and the anti-gout effect can be achieved after the long-term taking; the composition provided by the invention is derived from extracts of medicinal and edible plants, is safe and effective, has a good taste, and can be taken for a long time.

Description

Technical Field

[0001] The present invention relates to the technical field of pharmaceutical processing, and in particular to a preparation process and application of a uric acid-lowering composition based on medicinal and edible materials. Background Art

[0002] Hyperuricemia (HUA) is a serious metabolic disease caused by increased uric acid production or obstructed uric acid excretion in the human body, which leads to increased uric acid content in the blood. It is the fourth most common basic disease after hypertension, diabetes and hyperlipidemia. Clinically, hyperuricemia is usually diagnosed when the fasting blood uric acid level exceeds 420μmol / L twice on different days. Hyperuricemia has a series of complications, the most common of which is gout, which is the deposition of urate crystals in the joints causing joint damage; the second is renal function damage, which is mainly caused by the continuous deposition of urate crystals in the renal tubules and the renal inflammation reaction; in addition, common complications include hypertension, fatty liver, cardiovascular disease, metabolic syndrome, obesity and chronic kidney disease. According to the "White Paper on Hyperuricemia and Gout Trends in China" (2021), the overall prevalence of hyperuricemia in my country is 13.3%, and the number of patients is about 177 million. In recent years, hyperuricemia in my country has shown an upward and younger trend. Young hyperuricemia and gout patients aged 18-35 account for nearly 60%. It is precisely because hyperuricemia seriously endangers human health and has become a national health issue that cannot be ignored. Therefore, how to treat hyperuricemia has become a hot topic of research for many medical and scientific researchers.

[0003] At present, the drugs used clinically to treat hyperuricemia can be divided into two major categories. The first category is to inhibit the production of uric acid in the body. The drugs include allopurinol, febuxostat, febuxostat and topiroxostat. This type of drug mainly inhibits the activity of xanthine oxidase (XOD), restricting the body's metabolism of purine and other nucleoside substances into uric acid, thereby reducing the concentration of uric acid in the blood to achieve the therapeutic effect. However, this type of drug has serious reactions. For example, allopurinol can cause nephrotoxicity, gastrointestinal intolerance, rash and allergic syndrome; febuxostat causes liver damage and cardiovascular side effects; and febuxostat increases the risk of sudden cardiac death. The second major category is to promote the excretion of uric acid in the body. The drugs include benzbromarone, probenecid and sulfinpyrazone. However, these drugs also have serious reactions. For example, the long-term use of benzbromarone has caused many deaths. Therefore, in 2003, the United States and some European countries announced a clinical ban on the use of benzbromarone as a uric acid excretion drug to treat hyperuricemia. Therefore, there is an urgent need for safe and effective uric acid-lowering drugs or functional foods on the market. At present, hyperuricemia requires long-term medication to control blood uric acid within a normal range. Therefore, the invention is required to have a uric acid-lowering effect and can be safely consumed for a long time.

[0004] Since edible and medicinal substances refer to animal and plant medicinal materials with traditional consumption customs and included in the national management standards for traditional Chinese medicines, including food, condiments and spices, the biggest feature of edible and medicinal varieties is that they are non-toxic and can be eaten for a long time. Therefore, they have natural advantages in developing functional foods or health products for long-term use. The present discovery of developing safe and effective uric acid-lowering compositions based on edible and medicinal materials can greatly fill and meet market demand. Summary of the invention

[0005] In view of the above situation, in order to make up for the above existing defects, the present invention provides a preparation process and application of a uric acid-lowering composition based on medicinal and edible medicinal materials. The present invention uses honeysuckle, chicory, polygonatum, poria, mulberry leaf, dandelion, galangal, ginseng and cistanche as main raw materials, adopts a refining process to obtain extracts, and uses maltitol and steviol glycosides as sweeteners to develop a uric acid-lowering and anti-gout composition. On the one hand, the composition can inhibit the formation of uric acid, such as honeysuckle, chicory, polygonatum, poria, mulberry leaf, dandelion and galangal all have the ability to inhibit xanthine oxidase activity; on the other hand, it can promote the excretion of uric acid, such as chicory and dandelion in the formula can inhibit uric acid transporters URAT1 and GLUT9 to promote the excretion of uric acid; at the same time, it can reduce the complications of hyperuricemia, such as honeysuckle, dandelion and galangal in the formula have analgesic and anti-inflammatory effects, and can improve the symptoms of gout.

[0006] The present invention provides the following technical solution: The uric acid lowering composition based on edible and medicinal materials proposed in this solution is characterized in that the composition consists of: ginseng, Cistanche deserticola, honeysuckle, chicory, polygonatum, poria, mulberry leaf, gardenia and galangal.

[0007] Furthermore, the Chinese medicine composition of medicinal materials is composed of 5-10 parts of ginseng, 5-10 parts of Cistanche deserticola, 30-35 parts of honeysuckle, 15-20 parts of chicory, 15-20 parts of polygonatum, 10-15 parts of poria, 15-20 parts of mulberry leaves, 15-20 parts of gardenia, 15-20 parts of dandelion and 15-20 parts of galangal.

[0008] Furthermore, the Chinese medicine composition of medicinal materials is composed of 6-9 parts of ginseng, 6-9 parts of Cistanche deserticola, 31-33 parts of honeysuckle, 16-19 parts of chicory, 16-19 parts of polygonatum, 11-13 parts of poria, 16-19 parts of mulberry leaves, 16-19 parts of gardenia, 16-19 parts of dandelion and 16-19 parts of galangal.

[0009] Among them, ginseng is ginseng that has been artificially cultivated for less than 5 years.

[0010] The preparation process of the uric acid-lowering composition based on edible and medicinal materials is characterized by comprising the following preparation steps:

[0011] Step 1: Take 5-10 parts of ginseng and 5-10 parts of Cistanche deserticola, add them into 70% ethanol which is 10-20 times higher than the total volume, and soak them for 30-60 minutes. Heat and reflux the extract for 2-3 times, and extract for 1.5-2 hours each time. Combine the filtrates, recover the solvent, and spray dry to obtain ginseng and Cistanche deserticola extract H1.

[0012] Step 2: 30-35 parts of honeysuckle, 15-20 parts of chicory, 15-20 parts of polygonatum, 10-15 parts of poria, 15-20 parts of mulberry leaves, 15-20 parts of gardenia, 15-20 parts of dandelion and 15-20 parts of galangal are mixed, and 10-20 times the volume of water is added to perform heating reflux extraction for 2-3 times, each extraction is 1.5-2h, the filtrate is combined, the solvent is recovered and then spray-dried to obtain extract H2;

[0013] Step 3: Add 1-2 parts of the ginseng and cistanche extract H1 obtained in step 1, 5-10 parts of the extract H2 obtained in step (2), 3-5 parts of maltitol and 0.01-0.05 parts of stevioside into a three-dimensional mixer, control the mixer speed to 4000-5000 r / min, and mix for 30-50 min to obtain a total mixed powder;

[0014] Step 4: Use an automatic packaging machine to pack the mixed powder in step 3 into bags of 5.0 g each, to obtain a uric acid-lowering and anti-gout composition.

[0015] Among them, honeysuckle is a commonly used Chinese medicine in my country with a long history of application. The 2010 edition of the Pharmacopoeia of the People's Republic of China lists the dried buds or flowers of the honeysuckle plant of the Caprifoliaceae as the authentic medicinal materials of honeysuckle. It is also one of the medicinal materials with the same origin of medicine and food. It has the effects of clearing away heat and detoxifying, cooling and dispersing wind and heat. It is commonly used for dry carbuncle, furuncle, throat paralysis, erysipelas, hot blood toxic dysentery, wind-heat cold, febrile fever and other diseases. In clinical Chinese medicine, prescriptions containing honeysuckle are used for the treatment of gout. Modern research reports that honeysuckle water extract and methanol extract can inhibit the activity of xanthine oxidase, inhibit the production of uric acid in the body, thereby reducing the level of uric acid. The main active ingredient in honeysuckle is chlorogenic acid. Studies have reported that chlorogenic acid has significant uric acid-lowering activity. It can not only significantly inhibit the activity of xanthine oxidase (XOD) to inhibit the production of uric acid, but also inhibit inflammatory factors such as interleukin and tumor necrosis factor, and has a significant therapeutic effect on the treatment of gout caused by hyperuricemia.

[0016] Among them, chicory is the dried root of the hairy chicory or chicory of the Asteraceae family. It tastes slightly bitter and salty, is cool in nature, and belongs to the liver, gallbladder, and stomach meridians. Chicory is a commonly used medicine for the Uyghur people. It has the effects of clearing the liver and gallbladder, strengthening the stomach and digestion, and diuresis and swelling. It has been included in the first volume of the "Pharmacopoeia of the People's Republic of China". Chicory is also a medicinal material for both medicine and food. It contains active ingredients such as polysaccharides, flavonoids, terpenes, phenolic acids, and phenylpropanoids. It has pharmacological effects such as protecting the liver, lowering blood sugar, resisting hyperuricemia, regulating blood lipids, and antibacterial, and has rich medicinal value. In recent years, the public has become more and more fond of health foods and functional drinks made from chicory. The theoretical system of traditional Chinese medicine believes that high blood uric acid and its deposition caused by abnormal uric acid metabolism belong to the category of "dampness" and "turbidity stagnation". Clinically, it often cuts into the spleen, stomach, intestines, kidneys and other organs to strengthen the spleen, eliminate dampness and eliminate turbidity, and has achieved good results. As a common Chinese medicine for strengthening the spleen and removing dampness, chicory is often used to treat gout and hyperuricemia, and the effect is remarkable. With the deepening of research, it has been confirmed that chicory can act on three aspects to adjust the body's uric acid metabolism, and has few adverse reactions, making it suitable for long-term use. First, chicory plays an important role in regulating uric acid excretion, which is consistent with its medicinal properties of "drying dampness and draining turbidity". First, chicory can upregulate the expression level of intestinal ABCG2, regulate intestinal flora, maintain the integrity of the intestinal barrier, and thus promote intestinal uric acid excretion; secondly, chicory promotes renal uric acid excretion and improves renal function by upregulating renal OAT1 and OAT3 and downregulating the expression of URAT1 and GLUT9. Second, chicory enters the liver meridian, can clear the liver and promote gallbladder, treat endogenous dampness and heat, and stagnation of liver and gallbladder. Pharmacological studies have shown that chicory can act on the liver, inhibit the activity of multiple purine metabolic enzymes, such as xanthine oxidase, 5′-nucleotidase, adenosine deaminase, purine nucleoside phosphorylase, guanine deaminase, etc., thereby inhibiting uric acid synthesis and effectively reducing uric acid levels. Third, chicory extract can reduce intestinal purine absorption and purine metabolic enzyme activity by down-regulating the expression of intestinal concentrating nucleoside transporter 2, thereby achieving the effect of lowering uric acid. In addition, chicory has anti-inflammatory activity, which can reduce the LPS / TLR4 axis inflammatory response by down-regulating serum lipopolysaccharide and TLR4 / NF-kB inflammatory pathway in the kidneys. It can also inhibit the NLRP3 signaling pathway, reduce the release of interleukin-1β, treat inflammation caused by uric acid, and significantly improve the symptoms of hyperuricemia. In addition, chicory acid, a bioactive ingredient in chicory, can protect the liver and inhibit inflammation, and is particularly suitable for treating hyperuricemia patients with insufficient liver function.

[0017] Among them, Polygonatum sibiricum is the rhizome of Polygonatum sibiricum, a perennial herb of the Liliaceae family. In 2002, the Ministry of Health of China listed it as a food substance with medicinal and edible properties. Polygonatum sibiricum is sweet and non-toxic, and enters the lung, spleen, and kidney meridians. It has the functions of moistening the lungs and nourishing the kidneys, and replenishing the spleen. It is suitable for dry cough with little sputum, chest pain, soreness of the waist and knees caused by deficiency of kidney yin, dizziness and fatigue, and spleen and stomach deficiency. Studies in recent years have shown that Polygonatum sibiricum polysaccharides have significant uric acid-lowering activity, and can inhibit the expression of xanthine oxidase (XOD) and related mRNA to reduce the production of uric acid. At the same time, Polygonatum sibiricum polysaccharides can also protect liver and kidney damage caused by hyperuricemia. Therefore, Polygonatum sibiricum is an ideal substance for the safe and effective treatment of hyperuricemia.

[0018] Among them, Poria cocos is one of the commonly used traditional Chinese medicines for the treatment of gout and hyperuricemia in clinical practice. It is also one of the common substances with medicinal and edible properties. It has the effects of promoting diuresis and removing dampness, strengthening the spleen, and calming the mind. Its main chemical components are polysaccharides, terpenes, steroids, fatty acids and other compounds. Studies have found that Poria cocos water extract can promote the excretion of uric acid by regulating the expression of uric acid-related transporter URAT1, and can also inhibit the activity of xanthine oxidase (XOD) to inhibit the production of uric acid. Literature reports believe that Poria cocos polysaccharide is its effective ingredient for lowering uric acid.

[0019] Among them, mulberry leaves are mainly distributed in Asia, Europe and North America. China is the origin of mulberry. In addition to being used to raise silkworms, mulberry leaves are also a medicinal resource. The medicinal value of mulberry leaves was first seen in "Shennong's Herbal Classic". In 2002, the Ministry of Health of China listed it as a food substance with medicinal and edible properties. Mulberry leaves contain bioactive substances such as flavonoids, polysaccharides, alcohols, alkaloids and polyphenols. Studies have shown that mulberry leaf flavonoids have a significant effect on lowering uric acid, and can significantly reduce creatinine, uric acid nitrogen, triglycerides, malondialdehyde, free fatty acid levels and kidney coefficients, liver coefficients, thereby achieving the effect of regulating blood uric acid levels and protecting the kidneys. Mulberry leaf flavonoids can significantly inhibit the activity of xanthine oxidase (XOD) and thus inhibit the production of uric acid, reducing the level of uric acid in the blood of patients with hyperuricemia.

[0020] Among them, dandelion is a perennial herb of the genus Taraxacum in the Asteraceae family. It is included in the first list of Chinese medicine and food homology catalogs and has the effect of diuresis and stranguria. Before 2020, dandelion was not found to have the effect of lowering uric acid. In recent years, studies have found that dandelion extract has significant uric acid lowering activity. Dandelion extract can significantly inhibit the activity of xanthine oxidase (XOD), thereby inhibiting the production of uric acid in the body, and can also inhibit the activity of URAT1 and GLUT9 enzymes to promote the excretion of uric acid in the body. Its main components, flavonoids and polyphenols, are the material basis for its uric acid lowering.

[0021] Among them, galangal belongs to the dried tuber of the ginger plant galangal, which is included in the first list of Chinese medicine and food homology. Its main components are flavonoids and polyphenol compounds, which have anti-inflammatory and antioxidant activities. Galangal extract can significantly inhibit the activity of xanthine oxidase and inhibit the production of uric acid in the body, thereby achieving the effect of lowering uric acid.

[0022] Among them, ginseng and Cistanche are both tonic drugs. Although there is no report on the activity of lowering uric acid, insufficient renal function or insufficient renal power is an important reason for the inability of uric acid to be discharged from the body normally, thus causing high uric acid in the blood. Ginseng and Cistanche are both yang-tonifying Chinese medicinal materials, which can improve renal function and promote renal power, thereby promoting the excretion of uric acid and indirectly reducing the level of uric acid in the body.

[0023] The beneficial effects achieved by the present invention using the above structure are as follows: the present invention uses honeysuckle, chicory, polygonatum, poria, mulberry leaf, dandelion, galangal, ginseng and cistanche as main raw materials, adopts a refining process to obtain an extract, uses maltitol and stevioside as sweeteners, and develops a uric acid-lowering and gout-resistant composition. On the one hand, the composition can inhibit the formation of uric acid, such as honeysuckle, chicory, polygonatum, poria, mulberry leaf, dandelion and galangal all have the ability to inhibit xanthine oxidase activity; on the other hand, it can promote the excretion of uric acid, such as chicory and dandelion in the formula can inhibit uric acid transporters URAT1 and GLUT9 to promote the excretion of uric acid; at the same time, it can alleviate the complications of hyperuricemia, such as honeysuckle, dandelion and galangal in the formula have analgesic and anti-inflammatory effects.

[0024] The invention can improve the symptoms of gout. The invention has the beneficial effect that a variety of medicinal and edible plant extracts and sweeteners are compounded, and the invention can inhibit the activity of xanthine oxidase in the patient's body, thereby inhibiting the production of uric acid in the body, and promoting the excretion of uric acid in the patient's body, thereby effectively reducing the patient's blood uric acid level, and long-term use can achieve an anti-gout effect;

[0025] The compositions of the present invention are all derived from extracts of plants that are both medicinal and edible, are safe and effective, have good taste, and can be taken for a long time. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 is the uric acid value of different groups of mice of the present invention;

[0027] Figure 2 This is a chart showing the uric acid status of the volunteers tested in the present invention;

[0028] Figure 3 The total ion current diagram (A) and ultraviolet spectrum (B) of the composition of the present invention;

[0029] Figure 4 It is the main component of the composition of the present invention and has uric acid lowering activity. DETAILED DESCRIPTION

[0030] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all of the embodiments; based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0031] refer to Figure 1-4 As shown, the present invention is further described below in conjunction with specific embodiments.

[0032] Experimental Example 1

[0033] Experimental purpose: To test the uric acid-lowering effect of the invented uric acid-lowering composition on hyperuricemia mice.

[0034] Experimental materials: Sodium carboxymethyl cellulose, purchased from Shanghai Yuanye Biotechnology Co., Ltd., batch number: 9004-32-4; ​​Potassium oxonate, purchased from Shanghai Yuanye Biotechnology Co., Ltd., batch number: 2207-75-2; Hypoxanthine, purchased from Shanghai Yuanye Biotechnology Co., Ltd., batch number: 68-94-0; Allopurinol, purchased from Shanghai Yuanye Biotechnology Co., Ltd., batch number: 315-30-0; Uric acid detection test kit, purchased from Nanjing Jiancheng Bioengineering Institute, batch number: 20230921.

[0035] Experimental animals: SPF-grade KM mice were purchased from Hunan Slake Jingda Experimental Animal Co., Ltd., license SCXK (Xiang) 2019-0004.

[0036] Experimental instruments: Refrigerated centrifuge (Gene Company Limited). Full wavelength multifunctional microplate reader from Tecan Austria GmbH.

[0037] Experimental method: After adaptive feeding, 70 KM mice were randomly divided into 7 groups: blank, model, control, and different doses of the combination (50, 100, 200, 400 mg / kg); the model was established by oral gavage of hypoxanthine and potassium oxonate seven days before the experiment. During this period, the uric acid value of the mice was ≥126 μmol / L, which proved that the model was successfully established; after the successful establishment of the model, the control group and the treatment group were given corresponding drugs for oral gavage for seven consecutive days, and samples were collected 1 hour after the end of the seventh day; the blood samples were centrifuged to obtain serum, and the uric acid test kit of Nanjing Jiancheng Bioengineering Institute was used for detection. The experimental results are as follows Figure 1 shown.

[0038] Experimental results and conclusions: Figure 1It can be seen that the uric acid level in the model group was significantly higher than that in the normal group, indicating that the hyperuric acid model was successfully established; taking different doses of Prescription A can significantly reduce the uric acid level in the hyperuricemia model. The above experimental results show that Prescription A can reduce the level of uric acid in hyperuricemia, and 400 mg / kg has the best uric acid-lowering effect, which can reduce the uric acid of hyperuricemia mice to normal levels.

[0039] Experimental Example 2

[0040] Experimental purpose: To detect the acute toxicity and long-term toxicity of the invented composition.

[0041] (1) Acute toxicity test:

[0042] Experimental materials: 40 20g male KM mice, composition.

[0043] Experimental plan: After adaptive feeding, 40 mice were randomly divided into four groups, namely blank, low, medium and high, for gavage. The blank group was gavaged with the same dose of water, while the low, medium and high groups were gavaged with doses of 100 times, 200 times and 300 times the initial treatment dose, namely 5g / kg, 10g / kg and 20g / kg respectively. Gavage was performed only on the first day, and the death of mice was continuously observed for the next 14 days. The mice were killed on the seventh day to observe the organ lesions of the mice.

[0044] Experimental results: No mice died and no organ lesions were found.

[0045] (2) Chronic toxicity test:

[0046] Experimental materials: 40 male KM mice weighing 20-23 g, composition.

[0047] Experimental plan: After adaptive feeding, 40 mice were randomly divided into four groups: blank, low, medium, and high, and then gavaged. The blank group was gavaged with the same dose of water, and the low, medium, and high groups were gavaged with doses of 50 mg / kg, 100 mg / kg, and 200 mg / kg, respectively. The mice were gavaged continuously for 90 days, and the death of the mice was observed. The mice were killed on the 90th day to observe the pathological changes of their organs.

[0048] The experimental results showed that no mice died and no pathological changes occurred in the liver and kidney of mice. The results of acute toxicity and long-term toxicity experiments of Recipe A showed that Recipe A was safe and could be consumed for a long time.

[0049] Experimental Example 3

[0050] Experimental purpose: To detect the uric acid-lowering effect of the invented composition on patients with hyperuricemia.

[0051] Experimental subjects and methods: Subject inclusion criteria: fasting blood uric acid value ≥ 420μmol / L, a total of 5 volunteers were included, with an age range of 25-63 years old. The volunteers took 1 pack of the invented composition every morning, noon and evening, 150mL warm water, 3 times a day, for 15 consecutive days. Before taking the test substance, the uric acid value was tested on an empty stomach in the morning. After taking it for 15 days, the uric acid value was tested on an empty stomach in the morning to evaluate the uric acid-lowering effect of the test substance on volunteers with high uric acid.

[0052] Experimental results and conclusions: Figure 2 The uric acid levels of the five volunteers with high uric acid levels decreased by 2% to 33.8%, indicating that the composition has a 100% uric acid-lowering efficacy. Among them, the uric acid of volunteer AD returned to normal levels after 15 days of testing, and the cure rate was 80%. The above data show that the composition of the invention has a significant uric acid-lowering effect and has great market prospects and value.

[0053] Experimental Example 4

[0054] Experimental purpose: To detect the main components of the invented composition based on mass spectrometry technology, evaluate the uric acid-lowering activity of the main components, and clarify the main active ingredients of the invented composition.

[0055] Experimental materials and methods: 1290UPLC-Q-TOF-MS (6540 series, Agilent, USA), chlorogenic acid (purity ≧98%), neochlorogenic acid (purity ≧98%), cryptochlorogenic acid (purity ≧98%), isochlorogenic acid A (purity ≧98%), isochlorogenic acid B (purity ≧98%), isochlorogenic acid C (purity ≧98%), caffeic acid (purity ≧98%), salvianolic acid B (purity ≧98%) ), citric acid (purity ≧98%), strychnine (purity ≧98%) and other 10 standard substances were purchased from Wuhan Tianzhi Biotechnology Co., Ltd., and 130 male Kunming mice weighing 20-23g were used; firstly, the main components in the invention composition were determined based on UPLC-Q-TOF-MS technology, and then the uric acid-lowering activity of the main components was evaluated. The evaluation method was consistent with Experimental Example 1, and the dosage of the standard substance was 30 mg / kg.

[0056] Experimental results and conclusions:

[0057] from Figure 4 It can be seen that the main components of the composition of the invention are chlorogenic acid, neochlorogenic acid, cryptochlorogenic acid, caffeic acid, citric acid, isochlorogenic acid A, isochlorogenic acid C and strychnine, all of which are polyphenolic compounds, among which chlorogenic acid has the highest content. Figure 4It can be seen that chlorogenic acid, neochlorogenic acid, cryptochlorogenic acid and isochlorogenic acid A all have uric acid-lowering activity, among which chlorogenic acid has the best uric acid-lowering effect, and it is the main uric acid-lowering active ingredient of the invented composition.

[0058] The basic principles and main features of the present invention and the advantages of the present invention are shown and described above. For those skilled in the art, it is obvious that the present invention is not limited to the details of the above exemplary embodiments, and the present invention can be implemented in other specific forms without departing from the spirit or basic features of the present invention; therefore, no matter from which point of view, the embodiments should be regarded as exemplary and non-restrictive. The scope of the present invention is limited by the attached claims rather than the above description. Therefore, it is intended to include all changes within the meaning and scope of the equivalent elements of the claims in the present invention, and any figure marks in the claims should not be regarded as limiting the claims involved.

[0059] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A uric acid-lowering composition based on medicinal and edible medicinal materials, characterized in that: It includes ginseng, Cistanche deserticola, honeysuckle, chicory, polygonatum, poria, mulberry leaf, gardenia and galangal.

2. A uric acid lowering composition based on medicinal and edible medicinal materials according to claim 1, characterized in that: The Chinese medicinal material composition comprises 5-10 parts of ginseng, 5-10 parts of cistanche deserticola, 30-35 parts of honeysuckle, 15-20 parts of chicory, 15-20 parts of polygonatum, 10-15 parts of tuckahoe, 15-20 parts of mulberry leaves, 15-20 parts of gardenia, 15-20 parts of dandelion and 15-20 parts of galangal.

3. A uric acid lowering composition based on medicinal and edible medicinal materials according to claim 2, characterized in that: The Chinese medicinal material composition is composed of 6-9 parts of ginseng, 6-9 parts of cistanche deserticola, 31-33 parts of honeysuckle, 16-19 parts of chicory, 16-19 parts of polygonatum, 11-13 parts of tuckahoe, 16-19 parts of mulberry leaves, 16-19 parts of gardenia, 16-19 parts of dandelion and 16-19 parts of galangal.

4. A preparation process for a uric acid-lowering composition based on edible and medicinal materials according to claims 1-3, characterized in that: Step 1: Take 5-10 parts of ginseng and 5-10 parts of Cistanche deserticola, add them into 70% ethanol which is 10-20 times higher than the total volume, and soak them for 30-60 minutes. Heat and reflux the extract for 2-3 times, and extract for 1.5-2 hours each time. Combine the filtrates, recover the solvent, and spray dry to obtain ginseng and Cistanche deserticola extract H1. Step 2: Mix 30-35 parts of honeysuckle, 15-20 parts of chicory, 15-20 parts of polygonatum, 10-15 parts of poria, 15-20 parts of mulberry leaves, 15-20 parts of gardenia, 15-20 parts of dandelion and 15-20 parts of galangal, add 10-20 times the volume of water, heat and reflux for extraction 2-3 times, each extraction for 1.5-2h, combine the filtrate, recover the solvent and spray-dry to obtain extract H2; Step 3: add 1-2 parts of the ginseng and Cistanche extract H1 obtained in step 1, 5-10 parts of the extract H2 obtained in step 2, 3-5 parts of maltitol and 0.01-0.05 parts of stevioside into a three-dimensional mixer, control the speed of the three-dimensional mixer to 4000-5000 r / min, and mix for 30-50 min to obtain a total mixed powder; Step 4: Use an automatic packaging machine to pack the mixed powder in step 3 into bags of 5.0 g each, to obtain a uric acid-lowering and anti-gout composition.

5. The uric acid lowering composition based on edible and medicinal materials according to claim 4, characterized in that: Ginseng is ginseng that has been artificially cultivated for less than 5 years.

Images